References
- Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007;117:112–121.
- Zenz T, Dohner H, Stilgenbauer S. Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007;20:439–453.
- Calin GA, Dumitru CD, Shimizu M, et al Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002;99:15524–15529.
- de Graaf AO, van Krieken JH, Tönnissen E, et al Expression of C-IAP1, C-IAP2 and SURVIVIN discriminates different types of lymphoid malignancies. Br J Haematol 2005;130:852–859.
- Ali MA, Rosati R, Pettit GR, Kalemkerian GP. Dolastatin 15 induces apoptosis and BCL-2 phosphorylation in small cell lung cancer cell lines. Anticancer Res 1998;18:1021–1026.
- Messmer BT, Messmer D, Allen SL, et al In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755–764.
- Del Poeta D, Del Principe MI, Maurillo L, et al Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. Leuk Lymphoma 2010;51:95–106.
- Grever MR, Lucas DM, Dewald GW, et al Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III trial E2997. J Clin Oncol 2007;25:799–804.
- Stilgenbauer S, Eichhorst BF, Busch R, et al Biologic and clinical markers for outcome after fludarabine (F) or F plus cyclophosphamide (FC) – comprehensive analysis of the CLL4 trial of the GCLLSG. Blood 2008;112(Suppl.): (Abstract 2089).
- Döhner H, Stilgenbauer S, Benner A, et al Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910–1916.